VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma

Published:2017-01 Issue: Volume:Volume 10 Page:217-226
ISSN:1178-6930
Container-title:OncoTargets and Therapy
language:en
Short-container-title:OTT

Author:

Nadiminti Kalyan,Abbi Kamal Kant Singh,Mott Sarah,Dozeman Lindsay,Tricot Annick,Schultz Allyson,Behrends Sonya,Zhan Fenghuang,Tricot Guido

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Leptotrichia Bacteremia After Chemotherapy for Hematologic Malignancy;American Journal of Therapeutics;2019-11

2. A phase I/II study of escalating doses of thalidomide in conjunction with bortezomib and high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma;Bone Marrow Transplantation;2019-05-17

3. European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when;Haematologica;2018-08-31

4. C-Reactive Protein Monitoring Predicts Neutropenic Fever Following Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma;Cureus;2018-07-08

5. Bloodless tandem autologous transplant in Jehovah’s Witness patients;Bone Marrow Transplantation;2018-05-24

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP